Crystalline bis- and tris-hydrochloride salt of elamipretide
Disclosed are crystalline forms of the bis- and tris-(hydrochloride) salts of D-Arg-Tyr(2,6-DiMe)-Lys-Phe-NH 2 , which is also known as MTP-131.
1. A crystalline form of a bis-(hydrochloride) salt of Compound (I),
wherein said crystalline form has peaks in its XRPD pattern at values of two theta as listed in Table 2A:
TABLE 2A
d spacing
Height
Relative intensity
2θ (°)
(A°)
(cps)
(%)
6.40
13.79726
1343
28
6.98
12.65711
406
9
7.88
11.20719
160
3
9.05
9.76484
112
2
9.84
8.97904
1550
33
10.18
8.67918
186
4
11.65
7.58843
340
7
13.06
6.77213
4732
100
16.88
5.24746
715
15
19.09
4.64608
790
17
20.61
4.30611
289
6
24.21
3.67305
113
2
24.84
3.58126
433
9
26.33
3.38163
298
6
27.44
3.24777
327
7
28.59
3.11934
158
3
29.73
3.00251
480
10.
2. A crystalline form of a bis-(hydrochloride) salt of Compound (I),
wherein said crystalline form has peaks in its XRPD pattern as shown in FIG. 2 .
3. A crystalline form of a bis-(hydrochloride) salt of Compound (I),
wherein said crystalline form has peaks in its XRPD pattern at values of two theta (° 2) of: 6.4, 9.8, 13.1, 16.9, 19.1, and 29.7.
4. The crystalline form of claim 3 , wherein said crystalline form has peaks in its XRPD pattern at values of two theta (° 2) of: 6.4, 7.0, 7.9, 9.1, 9.8, 10.2, 11.7, 13.1, 16.9, 19.1, 20.6, 24.2, 24.8, 26.3, 27.4, 28.6, and 29.7.
5. A crystalline form of a tris-(hydrochloride) salt of Compound (I),
wherein said crystalline form has peaks in its XRPD pattern at values of two theta as listed in Table 10A:
TABLE 10A
Pos.
d-spacing
Height
Rel. Int.
[°2θ]
[Å]
[cts]
[%]
5.6826
15.55252
48.89
5.06
6.669
13.25428
16.7
1.73
8.1507
10.84783
650.66
67.29
9.2697
9.54072
154.41
15.97
9.8231
9.00438
277.37
28.68
11.0495
8.00758
264.45
27.35
11.4729
7.713
393.18
40.66
12.3925
7.14266
360.31
37.26
12.8405
6.89444
63.27
6.54
13.6472
6.48865
237.2
24.53
14.3699
6.16392
107.3
11.1
14.8755
5.95554
245.56
25.39
15.5909
5.68384
369.87
38.25
15.8566
5.58918
690.32
71.39
17.1543
5.16919
226.03
23.38
17.5374
5.05713
195.25
20.19
17.953
4.94097
47.6
4.92
18.525
4.78968
58.51
6.05
18.9247
4.68942
87.39
9.04
19.3114
4.59638
76.49
7.91
19.6517
4.51754
125.18
12.95
20.1474
4.40749
317.33
32.82
20.3935
4.35487
89.76
9.28
20.6086
4.3099
83.34
8.62
21.1328
4.20415
68.92
7.13
21.8535
4.06712
319.84
33.08
22.1439
4.01443
737.79
76.3
22.6006
3.93432
204.99
21.2
23.0153
3.86436
966.96
100
23.4697
3.79057
560.81
58
23.9736
3.71203
182.25
18.85
24.2292
3.67344
181.59
18.78
24.8488
3.58324
192.35
19.89
25.46
3.49858
152.72
15.79
25.8659
3.44459
116.17
12.01
26.4139
3.37436
205.95
21.3
26.945
3.30905
134.94
13.96
27.4489
3.24943
407.87
42.18
27.9725
3.18979
284.45
29.42
28.1692
3.16796
237.71
24.58
28.7691
3.10326
99.86
10.33
29.6808
3.00998
36.29
3.75
30.7678
2.90607
48.38
5
31.7169
2.82124
134.12
13.87
33.0072
2.71384
72.56
7.5
33.8578
2.64759
76.16
7.88.
6. A crystalline form of a tris-(hydrochloride) salt of Compound (I),
wherein said crystalline form has peaks in its XRPD pattern as shown in FIG. 9 .
7. A crystalline form of a tris-(hydrochloride) salt of Compound (I),
wherein said crystalline form has peaks in its XRPD pattern at values of two theta (° 2) of: 8.1, 11.5, 15.6, 15.9, 22.1, 23.0, and 27.4.
8. The crystalline form of claim 7 , wherein said crystalline form has peaks in its XRPD pattern at values of two theta (° 2) of: 8.1, 9.8, 11.0, 11.5, 12.4, 14.9, 15.6, 15.9, 20.1, 21.8, 22.1, 23.0, 27.4, and 28.0.
9. A composition, comprising the crystalline form of claim 1 .
10. A process for making a pharmaceutical composition comprising Compound (I),
which comprises dissolving the crystalline form of claim 1 .
11. A process for making a pharmaceutical composition comprising Compound (I),
which comprises dissolving the crystalline form of claim 5 .
12. A process for making a pharmaceutical composition comprising Compound (I),
which comprises dissolving the crystalline form of claim 1 .
13. A composition, comprising the crystalline form of claim 2 .
14. A composition, comprising the crystalline form of claim 3 .
15. A composition, comprising the crystalline form of claim 4 .
16. A composition, comprising the crystalline form of claim 5 .
17. A composition, comprising the crystalline form of claim 6 .
18. A composition, comprising the crystalline form of claim 7 .
19. A composition, comprising the crystalline form of claim 8 .